Full Product Name
GFAP Antibody, Clone S206A-8: Dylight 405
Product Synonym Names
Mouse Anti-Human GFAP Monoclonal IgG1; GFAP Antibody: Dylight 405; Glial fibrillary acidic protein Antibody; Intermediate filament protein Antibody; Astrocyte Antibody; gfapl Antibody; DKFZp459C0729 Antibody; MGC139638 Antibody; FLJ45472 Antibody; AI836096 Antibody; GFAP Antibody
Product Gene Name
anti-GFAP antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P14136
Species Reactivity
Human, Mouse, Rat
Specificity
Detects ~50 kDa. Cross-reacts with GFAP-R416W and other GFAP mutant proteins.
Purity/Purification
Protein G Purified
Form/Format
PBS pH 7.4, 50% Glycerol, 0.1% Sodium Azide
Concentration
1 mg/ml (lot specific)
Immunogen
Synthetic peptide amino acids 411-422 (KTVEMRDGEVIK) of human GFAP; 100% identical in rat and mouse
Cellular Localization
Cytoplasm
Certificate of Analysis
1 ug/ml was sufficient for detection of GFAP in 20 ug of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Product Notes
Conjugated primary antibodies can be good options or alternatives to secondary antibody's for detecting a target protein. The lab manufactures a conjugated antibody from a primary parent antibody by attaching (conjugating) an available tag such as a fluorophore or protein, allowing detection of the target protein without using a secondary antibody. Conjugated primary antibodies may potentially be used to replace primary/secondary antibody pairs in various applications, such as Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry, Fluorescence-activated cell sorting, F?rster Resonance Energy Transfer (FRET). Immunocytochemistry, Immunofluorescence, Immunohistochemistry, or Western Blot. The suitability of applications for conjugates are user determined and we cannot guarantee that any antibody-conjugate combination has been tested for use in a particular application.
Please note: Conjugate tags may potentially bind in the antibody paratope, which can limit binding of the antibody to the antigen. Binding in the antibody paratope may affect the ability of the antibody to bind to the corresponding antigen (protein target) in various species and applications. There is no way to confirm or guarantee the location of the antibody tag as we cannot control the binding of the conjugate to the antibody. Researchers are responsible for evaluating antibody conjugates for the suitability of their applications.
Preparation and Storage
Store at-20 degree C.
Other Notes
Small volumes of anti-GFAP antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-GFAP antibody
The 50 kDa type III intermediate filament protein glial fibrillary acidic protein (GFAP) is a major structural component of astrocytes. GFAP associates with the calcium binding protein annexin II-p2 and S-100. Association with these proteins together with phosphorylation regulates GFAP polymerization. Astroycytes respond to brain injury by proliferatin (astrogliosis), and one of the first events to occur during astrocyte proiliferation is increased GFAP expression. Interestingly, antibodies to GFAP have been detected in individuals with dementia.
Product Categories/Family for anti-GFAP antibody
Neuroscience; Cell Markers; Glial Markers; Astrocyte Markers
Applications Tested/Suitable for anti-GFAP antibody
Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)
Application Notes for anti-GFAP antibody
WB: 1:1000
Immunocytochemistry (ICC) of anti-GFAP antibody
Immunocytochemistry/Immunofluorescence analysis using Mouse Anti-GFAP Monoclonal Antibody, Clone S206A-8 at 1:100 for 60 min at RT. Secondary Antibody: Goat Anti-Mouse ATTO 488 at 1:100 for 60 min at RT. Counterstain: Phalloidin Texas Red F-Actin stain; DAPI (blue) nuclear stain at 1:1000, 1:5000 for 60min RT, 5min RT. Localization: Cytoplasm. Magnification: 60X. (A) DAPI (blue) nuclear stain. (B) Phalloidin Texas Red F-Actin stain. (C) GFAP Antibody. (D) Composite.
Western Blot (WB) of anti-GFAP antibody
Western Blot analysis of Rat Brain Membrane showing detection of GFAP protein using Mouse Anti-GFAP Monoclonal Antibody, Clone S206A-8 at 1:250.
NCBI/Uniprot data below describe general gene information for GFAP. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001124491.1
[Other Products]
NCBI GenBank Nucleotide #
NP_001124491.1
[Other Products]
UniProt Primary Accession #
P14136
[Other Products]
UniProt Related Accession #
P14136[Other Products]
NCBI Official Full Name
glial fibrillary acidic protein isoform 2
NCBI Official Synonym Full Names
glial fibrillary acidic protein
NCBI Official Symbol
GFAP??[Similar Products]
NCBI Official Synonym Symbols
ALXDRD
??[Similar Products]
NCBI Protein Information
glial fibrillary acidic protein
UniProt Protein Name
Glial fibrillary acidic protein
Protein Family
Glial fibrillary acidic protein
UniProt Gene Name
GFAP??[Similar Products]
UniProt Synonym Gene Names
GFAP??[Similar Products]
UniProt Entry Name
GFAP_HUMAN
NCBI Summary for GFAP
This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]
UniProt Comments for GFAP
GFAP: a class-III intermediate filament protein. A cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. An additional transcript variant isoform has been described, but its full length sequence has not been determined.
Protein type: Cytoskeletal
Chromosomal Location of Human Ortholog: 17q21
Cellular Component: membrane; cytoplasm; intermediate filament; cytosol
Molecular Function: integrin binding; structural constituent of cytoskeleton; kinase binding
Biological Process: Bergmann glial cell differentiation; extracellular matrix organization and biogenesis; regulation of neurotransmitter uptake; response to wounding; neurite regeneration; intermediate filament organization; astrocyte development
Disease: Alexander Disease
Product References and Citations for anti-GFAP antibody
1. Velasco M.E., et al. (1980) Cancer. 45:484. 2. Bonnin J.M., et al. (1984) Acta Neuropathology. 62:185. 3. Lee VM-Y., et al. (1984) J. Neurochem. 42:25-32 (1984). 4. Trojanowski JQ et al. (1986) J. Neurochem. 6(3): 650-660 (1986). 5. Schmidt ML et al; Lab Invest 56:282-294 (1987). 6. Kosik KS et al; Neuron 1:817-825 (1988). 7. Schmidt ML et al; Lab Invest 59:460-466 (1988). 8. Mokuna, K, et al: J Neurosci Res 23:396 (1989). 9. Molenaar, et al; Exp Neurology 108:1-9 (1990). 10. Tohyama T et al; Am J Pathol, 142:871-882 (1993). 11. Tohyama T et al; Am J Pathol 142:883-892 (1993). 12. Thilenius, A.R.B., et al; J. Immunol. 162(2): 643-650 (1999).
Research Articles on GFAP
1. serum levels do not increase in diabetic ketoacidosis patients without overt brain injury
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
